DB:GBI1

Stock Analysis Report

Executive Summary

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies.

Snowflake

Fundamentals

Excellent balance sheet and overvalued.

Risks

  • Genocea Biosciences has significant price volatility in the past 3 months.

Share Price & News

How has Genocea Biosciences's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

6.0%

DB:GBI1

2.4%

DE Biotechs

3.2%

DE Market


1 Year Return

-31.9%

DB:GBI1

-5.0%

DE Biotechs

-9.7%

DE Market

GBI1 underperformed the Biotechs industry which returned -5% over the past year.

GBI1 underperformed the Market in Germany which returned -9.7% over the past year.


Share holder returns

GBI1IndustryMarket
7 Day6.0%2.4%3.2%
30 Day-9.3%1.2%-4.4%
90 Day-23.8%6.3%-2.0%
1 Year-31.9%-31.9%-4.8%-5.0%-6.9%-9.7%
3 Year-91.6%-91.6%95.3%93.3%11.8%2.2%
5 Year-96.1%-96.1%26.2%24.0%26.9%9.5%

Price Volatility Vs. Market

How volatile is Genocea Biosciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Genocea Biosciences undervalued based on future cash flows and its price relative to the stock market?

2.12x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Genocea Biosciences to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Genocea Biosciences to establish if it is available at substantial discount.


Price Based on Earnings

Genocea Biosciences is loss making, we can't compare its value to the Europe Biotechs industry average.

Genocea Biosciences is loss making, we can't compare the value of its earnings to the Germany market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Genocea Biosciences, we can't assess if its growth is good value.


Price Based on Value of Assets

Genocea Biosciences is good value based on assets compared to the DE Biotechs industry average.


Next Steps

Future Growth

How is Genocea Biosciences expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

-19.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Genocea Biosciences is high growth as no revenue estimate data is available.

Genocea Biosciences is not considered high growth as it is expected to be loss making for the next 1-3 years.

Unable to compare Genocea Biosciences's revenue growth to the Germany market average as no estimate data is available.

Unable to compare Genocea Biosciences's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Genocea Biosciences's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Genocea Biosciences will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Genocea Biosciences performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Genocea Biosciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Genocea Biosciences's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Genocea Biosciences's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Genocea Biosciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Genocea Biosciences has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Genocea Biosciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Genocea Biosciences's financial position?


Financial Position Analysis

Genocea Biosciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Genocea Biosciences's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Genocea Biosciences's level of debt (35.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (20.1% vs 35.7% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 4.3x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Genocea Biosciences has sufficient cash runway for 1.6 years based on current free cash flow.

Genocea Biosciences has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -5.2% each year.


Next Steps

Dividend

What is Genocea Biosciences's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Genocea Biosciences's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Genocea Biosciences's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Genocea Biosciences has not reported any payouts.

Unable to verify if Genocea Biosciences's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Genocea Biosciences has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Genocea Biosciences's salary, the management and board of directors tenure and is there insider trading?

1.1yrs

Average management tenure


CEO

Chip Clark (50yo)

8.5yrs

Tenure

US$1,311,026

Compensation

Mr. William D. Clark, also known as Chip, M.B.A. has been the Chief Executive Officer and President at Genocea Biosciences, Inc. since February 2011. Mr. Clark served as Chief Financial Officer of Cubist P ...


CEO Compensation Analysis

Chip's remuneration is higher than average for companies of similar size in Germany.

Chip's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.1yrs

Average Tenure

48yo

Average Age

The average tenure for the Genocea Biosciences management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.2yrs

Average Tenure

56yo

Average Age

The tenure for the Genocea Biosciences board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$5,701,79726 Jun 19
GlaxoSmithKline plc
EntityCompany
Shares1,857,142
Max PriceUS$3.07
BuyUS$8,771,99725 Jun 19
New Enterprise Associates
EntityCompany
Shares2,857,142
Max PriceUS$3.07
BuyUS$4,158,33619 Feb 19
New Enterprise Associates
EntityCompany
Shares1,243,533.63
Max PriceUS$3.34
BuyUS$86,51025 Sep 18
George Siber
EntityIndividual
Role
Chairman of Advisory Board
Chairman of Scientific Advisory Board & Director
Shares20,425
Max PriceUS$4.28
BuyUS$4,62414 Sep 18
Michael Alfieri
EntityIndividual
Shares1,250
Max PriceUS$3.70

Ownership Breakdown


Management Team

  • Chip Clark (50yo)

    President

    • Tenure: 8.5yrs
    • Compensation: US$1.31m
  • Tom Davis (55yo)

    Chief Medical Officer

    • Tenure: 0.8yrs
  • Derek Meisner (48yo)

    Senior VP & General Counsel

    • Tenure: 0.8yrs
  • George Siber (74yo)

    Chairman of Scientific Advisory Board & Director

    • Tenure: 0.0yrs
    • Compensation: US$206.52k
  • Jessica Flechtner (47yo)

    Chief Scientific Officer

    • Tenure: 3.5yrs
    • Compensation: US$733.54k
  • Pam Carroll (55yo)

    Senior Vice President of Immun-Oncology

    • Tenure: 3.6yrs
    • Compensation: US$487.99k
  • Diantha Duvall (47yo)

    Chief Financial Officer

    • Tenure: 0.4yrs
  • Narinderjeet Singh (46yo)

    Senior VP of Pharmaceutical Sciences & Manufacturing

    • Tenure: 1.4yrs
  • Girish Aakalu (45yo)

    Chief Business Officer

    • Tenure: 0.7yrs

Board Members

  • Ken Bate (69yo)

    Chairman of the Board

    • Tenure: 0.7yrs
    • Compensation: US$99.83k
  • Chip Clark (50yo)

    President

    • Tenure: 8.5yrs
    • Compensation: US$1.31m
  • Ali Behbahani (43yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$106.03k
  • Michael Higgins (57yo)

    Director

    • Tenure: 4.5yrs
    • Compensation: US$94.55k
  • Katrine Bosley (51yo)

    Director

    • Tenure: 6.4yrs
    • Compensation: US$124.59k
  • George Siber (74yo)

    Chairman of Scientific Advisory Board & Director

    • Tenure: 0.0yrs
    • Compensation: US$206.52k
  • Howard Mayer (56yo)

    Director

    • Tenure: 2.4yrs
    • Compensation: US$84.55k
  • Ron Cooper (56yo)

    Director

    • Tenure: 3.2yrs
    • Compensation: US$90.55k
  • Chuck Drake

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs
  • Eric Tran

    Member of Scientific Advisory Board

    • Tenure: 0.0yrs

Company Information

Genocea Biosciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Genocea Biosciences, Inc.
  • Ticker: GBI1
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$84.725m
  • Listing Market Cap: US$76.413m
  • Shares outstanding: 26.15m
  • Website: https://www.genocea.com

Number of Employees


Location

  • Genocea Biosciences, Inc.
  • 100 Acorn Park Drive
  • 5th Floor
  • Cambridge
  • Massachusetts
  • 2140
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNCANasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDFeb 2014
GBI1DB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing C ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/23 22:08
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.